Company news

Jasper Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

December 9, 2023

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

November 29, 2023

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

November 1, 2023

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

October 31, 2023

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

October 8, 2023

Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer

September 24, 2023

Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 10, 2023

Jasper Therapeutics Strengthens Management Team with Key Appointments

August 1, 2023

Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

June 21, 2023

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

June 19, 2023

Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

June 12, 2023

Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023

Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board

May 9, 2023

Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources

April 12, 2023

Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations

April 9, 2023

Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer

March 22, 2023

Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update

March 7, 2023

Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

February 16, 2023

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

February 16, 2023

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients

February 15, 2023

Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2023

Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 26, 2023

Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

January 24, 2023

Jasper Therapeutics Announces Proposed Public Offering of Common Stock

January 23, 2023

Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

January 12, 2023

Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases

January 9, 2023

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant

January 3, 2023

Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

January 2, 2023

Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

November 9, 2022

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

September 25, 2022

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant

September 14, 2022

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

August 11, 2022

Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022

June 5, 2022

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

May 16, 2022

Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 11, 2022

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

April 27, 2022

Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

April 25, 2022

Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team

March 20, 2022

Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

March 17, 2022

Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer

February 27, 2022

Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

February 23, 2022

Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

November 11, 2021

Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy

November 8, 2021

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy

September 23, 2021

← Newer news releases

Decks

The 5 newest of 22 decks. Every deck is listed under its year.